Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 5
2007 4
2008 5
2009 5
2010 1
2011 2
2012 5
2013 11
2014 4
2015 7
2016 10
2017 9
2018 11
2019 8
2020 11
2021 10
2022 13
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Targeted therapy in NPM1-mutated AML: Knowns and unknowns.
Wang R, Xu P, Chang LL, Zhang SZ, Zhu HH. Wang R, et al. Among authors: zhu hh. Front Oncol. 2022 Sep 27;12:972606. doi: 10.3389/fonc.2022.972606. eCollection 2022. Front Oncol. 2022. PMID: 36237321 Free PMC article. Review.
Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY, Li JF, Zhu YM, Lin XJ, Wen LJ, Zhang F, Zhang YL, Zhao M, Fang H, Wang SY, Lin XJ, Qiao N, Yin W, Zhang JN, Dai YT, Jiang L, Sun XJ, Xu Y, Zhang TT, Chen SN, Zhu HH, Chen Z, Jin J, Wu DP, Shen Y, Chen SJ. Cheng WY, et al. Among authors: zhu hh. Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2211429119. doi: 10.1073/pnas.2211429119. Epub 2022 Nov 28. Proc Natl Acad Sci U S A. 2022. PMID: 36442087 Free PMC article.
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Mi YC, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. Zhu HH, et al. Blood Adv. 2023 Jul 11;7(13):2972-2982. doi: 10.1182/bloodadvances.2022008364. Blood Adv. 2023. PMID: 36799929 Free PMC article.
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, Xu G, Lu Y, Wei J, Mai W, Ye X, Meng H, Shen Y, Huang J, Yu W, Sun J, Sheng J, Yan X, Jin J, Zhu HH. Wang H, et al. Among authors: zhu hh. Lancet Haematol. 2022 Jun;9(6):e415-e424. doi: 10.1016/S2352-3026(22)00106-5. Epub 2022 May 2. Lancet Haematol. 2022. PMID: 35512726 Clinical Trial.
APL: Nemo finds its sea anemone.
Wang QF, Zhu HH. Wang QF, et al. Among authors: zhu hh. Blood. 2022 Dec 1;140(22):2311-2312. doi: 10.1182/blood.2022018020. Blood. 2022. PMID: 36454593 Free article. No abstract available.
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Wang QQ, Wang HF, Zhao JZ, Naranmandura H, Jin J, Zhu HH. Wang QQ, et al. Among authors: zhu hh. Br J Haematol. 2022 Jun;197(5):e58-e60. doi: 10.1111/bjh.18061. Epub 2022 Feb 17. Br J Haematol. 2022. PMID: 35176809 No abstract available.
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Xie M, Lu Y, Ouyang G, Li X, Shi T, Yang M, Le J, Hu H, Zhang L, Feng W, Meng H, Mai W, Wei J, Qian J, Xu G, Yang C, Zhou D, Lin Y, Qian S, Kuang Y, Zhang L, Zhu W, Yao G, Wu G, Hu S, Huang X, Wang Y, Tong H, Jin J, Zhu HH. Xie M, et al. Among authors: zhu hh. Br J Haematol. 2023 Sep;202(6):1119-1126. doi: 10.1111/bjh.18975. Epub 2023 Jul 11. Br J Haematol. 2023. PMID: 37434414 Clinical Trial.
Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xie M, Shi T, Jiang Q, Jia Y, Zhou D, Tong H, Jin J, Zhu HH. Xie M, et al. Among authors: zhu hh. Cancer. 2023 May 15;129(10):1523-1536. doi: 10.1002/cncr.34710. Epub 2023 Mar 7. Cancer. 2023. PMID: 36882308
123 results